OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age
| Autor: | CR Pinkerton, Andrew D.J. Pearson, Deborah A. Tweddle, Michael Cole, Ian Lewis, C. Ellershaw |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Cisplatin
Cancer Research medicine.medical_specialty Chemotherapy Cyclophosphamide business.industry medicine.medical_treatment medicine.disease Gastroenterology Carboplatin Surgery Sepsis chemistry.chemical_compound Oncology chemistry Internal medicine Neuroblastoma Pediatrics Perinatology and Child Health Toxicity medicine business Etoposide medicine.drug |
| Zdroj: | Medical and Pediatric Oncology. 36:239-242 |
| ISSN: | 1096-911X 0098-1532 |
| DOI: | 10.1002/1096-911x(20010101)36:1<239::aid-mpo1058>3.0.co;2-g |
| Popis: | OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Background: This paper reports the toxicity of OPEC/OJEC chemotherapy in stage 4 neuroblastoma patients over 1 year of age. Procedure. Ninety-five patients with stage 4 neuroblastoma received alternating courses of OPEC/ OJEC-vincristine 1.5 mg/m(2) (O), cisplatin 80 mg/m(2) (P), etoposide 200 mg/m(2) (E), cyclophosphamide 600 mg/m(2) (C), and carboplatin 500 mg/m(2) U), every 21 days if there was haematological recovery. Results. Seventy out of ninety-five (74%) patients completed seven or more courses and were evaluable for toxicity. Of these 70 patients, 33% had more than three episodes of fever and sepsis, 35% required more than five blood or platelet transfusions, 36% had grade 2 or more gastrointestinal toxicity and 9% had neurotoxicity. There was a median reduction in GFR of 32 ml/min/1.73 m(2) (-46 to 134) and there was one toxic death. Conclusions. OPEC/OJEC is a well-tolerated therapy for stage 4 neuroblastoma over 1 year of age. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text